ESPE Yearbook of Paediatric Endocrinology

In Brief: This phase 2 trial randomized 338 adults with overweight or obesity to once-weekly subcutaneous Retatrutide (LY3437943), a ‘triple agonist’ for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP1), and glucagon receptors, or placebo. Mean % change in body weight at 24 weeks was −7.2%, −12.9%, −17.3% and −17.5% in the 1-mg, 4-mg, 8-mg and 12-mg Retatrutide groups, compared with −1.6% in the placebo ...

Brief Summary: The study investigated how tirzepatide, a dual GIPR/GLP-1R agonist, modulates adipocyte nutrient metabolism by long-acting activation of the GIP receptor. It shows that tirzepatide enhances insulin signaling, glucose uptake, and lipid metabolism in adipocytes, contributing to improved metabolic outcomes in both fasted and fed states.Tirzepatide has recently been shown to have superior efficacy in reducing HbA1c, body weight, and serum trig...